dr. ellis on anticipated er /her2- breast cancer paradigms
Published 12 years ago • 485 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
0:50
dr. ellis on immunotherapy in her2 breast cancer
-
1:25
dr. ellis on neoadjuvant endocrine therapy for breast cancer
-
1:39
dr. ellis on abemaciclib in hr-positive breast cancer
-
0:22
copy of dr. ellis on abemaciclib in hr-positive breast cancer
-
1:52
dr. ellis on resistance to endocrine therapy in hr metastatic breast cancer
-
2:05
dr. ellis on potential impact of cdk4/6 inhibitors in breast cancer
-
1:24
dr. ellis on adjuvant cdk4/6 inhibition in hr-positive breast cancer
-
1:32
dr. ellis discusses genome forward breast cancer treatment
-
0:55
dr. ellis on measuring endocrine therapy efficacy with ki67
-
1:35
dr. ellis describes breast cancer heterogeneity
-
1:28
dr. dawar on challenges with neratinib in metastatic her2 breast cancer
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
1:12
dr. matthew ellis on heterogeneity impacting biomarker efficacy
-
0:20
copy of dr. ellis on the entrance of biosimilars into the field of oncology
-
0:57
dr. marks on the role of tkis in her2-positive breast cancer
-
1:32
dr. singh on dose dense acthp in her2 breast cancer
-
1:13
dr. hamilton on the efficacy of trastuzumab deruxtecan in her2-low breast cancer
-
3:20
dr. hurvitz on eliminating anthracyclines in her2 breast cancer treatment
-
1:00
dr. ellis considers the use of biosimilars in oncology